Appili Therapeutics Inc. (APLI.TO)
| Previous Close | 0.0750 |
| Open | 0.0750 |
| Bid | 0.0750 x N/A |
| Ask | 0.0750 x N/A |
| Day's Range | 0.0700 - 0.0750 |
| 52 Week Range | 0.0650 - 1.1400 |
| Volume | |
| Avg. Volume | 177,376 |
| Market Cap | 9.095M |
| Beta (5Y Monthly) | 1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4140 |
| Earnings Date | Jun 29, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.63 |
- Baystreet
Stocks in play: Appili Therapeutics Inc.
Announced its financial and operational results for the fiscal year ended March 31, 2022. The net loss ...
- Business Wire
Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results
HALIFAX, Nova Scotia, June 29, 2022--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Company’s strategy for fiscal 2023. All figures are stated in Canadian dollars unless otherwise stated.
- Business Wire
Appili Therapeutics Announces Closing of Public Offering of $4,500,000
HALIFAX, Nova Scotia, May 26, 2022--Appili Therapeutics Inc. (TSX: APLI) (the "Company" or "Appili") announced the closing of its previously announced public offering (the "Offering") of units (the "Units"). The Offering was made pursuant to an agency agreement, as amended, entered into between the Company, Bloom Burton Securities Inc. (the "Lead Agent") and Leede Jones Gable Inc. (collectively with the Lead Agent, the "Agents").
